Prognostic value of indoleamine 2,3 dioxygenase in patients with higher‐risk myelodysplastic syndromes treated with azacytidine

Hypomethylating agents (HMAs) are widely used in patients with higher‐risk myelodysplastic syndromes (MDS) not eligible for stem cell transplantation; however, the response rate is

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-08, Vol.190 (3), p.361-370
Main Authors: Müller‐Thomas, Catharina, Heider, Michael, Piontek, Guido, Schlensog, Martin, Bassermann, Florian, Kirchner, Thomas, Germing, Ulrich, Götze, Katharina S., Rudelius, Martina
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Azacitidine - pharmacology
Azacitidine - therapeutic use
Azacytidine
Biomarkers
Bone Marrow - pathology
CD8 antigen
CD8-Positive T-Lymphocytes - immunology
Cells, Cultured
Combined Modality Therapy
Dioxygenase
DNA Methylation - drug effects
Drug Therapy, Combination
Enzyme Induction - drug effects
Female
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Immune checkpoint
Immune Checkpoint Inhibitors - administration & dosage
Immune Checkpoint Inhibitors - therapeutic use
immunmodulation
Immunomodulation
indoleamine-2,3-dioxygenase
Indoleamine-Pyrrole 2,3,-Dioxygenase - biosynthesis
Indoleamine-Pyrrole 2,3,-Dioxygenase - blood
Indoleamine-Pyrrole 2,3,-Dioxygenase - genetics
Lymphocytes
Lymphocytes T
Macrophages - enzymology
Macrophages - ultrastructure
Male
Middle Aged
Myelodysplastic syndrome
myelodysplastic syndromes
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Prognosis
Risk
Stem cell transplantation
Tryptophan
Tryptophan - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypomethylating agents (HMAs) are widely used in patients with higher‐risk myelodysplastic syndromes (MDS) not eligible for stem cell transplantation; however, the response rate is
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16652